UNICREDIT BANK/CALL/BIOGEN IDEC/500/0.1/17.12.25 | Market Closed - Börse Stuttgart 19:11:41 20/05/2024 BST | ||
| 0.43 EUR | -15.69% |
|
| Current month | +95.45% | ||
| 1 month | +3,483.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 20/05/24 | 0.43 | -15.69% |
| 17/05/24 | 0.51 | 0.00% |
| 16/05/24 | 0.51 | 0.00% |
| 15/05/24 | 0.51 | +24.39% |
| 14/05/24 | 0.41 | +5.13% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 07:11 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1H9Q |
| ISIN | DE000HD1H9Q2 |
| Date issued | 28/12/2023 |
| Strike | 500 $ |
| Maturity | 17/12/2025 (576 Days) |
| Parity | 10 : 1 |
| Emission price | 1.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.11 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.05 € |
| Spread % | 9.80% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
231.6
USD
Average target price
285.9
USD
Spread / Average Target
+23.47%
- Stock Market
- Warrants
- Warrant
